Thanks to the European Commission, Biogen can extend Tecfidera monopoly for at least two...
According to an investigation by Follow the Money, a Dutch investigative journalism outlet, the European Commission restored the market exclusivity of Tecfidera, a multiple...
Expanding local production is essential for pandemic preparedness. It requires, however, transfer of technology.
Madam co-chairs, delegates,
This very week, from 7 to 9 April the 3rd World Local Production Forum is taking place in Abu Dhabi. Actions towards...
Time to put a stop to the abuse of orphan drug regulation- the latest...
Today, the Dutch Medical Journal (Nederlands Tijdschrift voor Geneeskunde) reported on the case of lutetium-octreotaat, a cancer drug developed by researchers in the Dutch...
Wrapping up 2023 with some noteworthy medicines, law and policy developments
Welcome to our 2023 end-of-the-year blog, our annual and highly-biased run-through of notable access to medicines events of the year that is about to...
A better way to solve a crisis: A new mechanism for incentivising R&D on...
Antimicrobial resistance is the ‘silent’ pandemic: Globally, it costs 5 million lives a year, and is set to rise to more than 8 million...
The European Commission’s compulsory licensing proposals are sensible but do not go far enough
An earlier version of this comment was published in Barron's on 21 July 2023. A Spanish translation of it is also available from El...
The Most Common Misunderstanding about Compulsory Licensing
The belief that a country can only use compulsory licensing in cases of public health emergencies is a myth that has proven difficult to...
Something is going terribly wrong with the EU Compulsory Licensing Regulation
This week the European Parliament will vote on amendments to the Commission’s proposed regulation of the European Parliament and the Council on compulsory licensing...
Brazil’s Federal Court Reviews Medicines Mailbox Patents
This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion...
Medicines Law & Policy statement at WHO PABS negotiations (IGWG 5)
Co-chairs, Thank you for the opportunity to say a few words.
My comments address issues related to technology transfer (TT), a topic we have been...